Mr. Horn joined Ultragenyx in October 2023 and is responsible for leading the company’s global finance, accounting, corporate strategy and investor relations functions.
He joined Ultragenyx from Vir Biotechnology, where he served as CFO and as a member of Vir’s founding management team, guiding the rapid transformation of Vir to a public, commercial-stage organization. Prior to Vir, Mr. Horn was at Biogen where he served first as vice president, strategic corporate finance and then as vice president, business planning. Previously, he held positions of increasing responsibility as a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Company, and as an equity research analyst in the Life Sciences group at UBS Group AG.
Mr. Horn received his B.A. in Economics from Princeton University and his M.B.A. from the Wharton School of the University of Pennsylvania.